{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:40:04Z","timestamp":1742953204085,"version":"3.40.3"},"reference-count":12,"publisher":"Baishideng Publishing Group Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Oncol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare primary epithelial lung cancer associated with the Epstein-Barr virus. Standard treatment guideline for PLELC is yet not to be established, surgery remains the primary treatment for early-stage PLELC, and platinum chemotherapy is the most common first-line treatment for advanced PLELC. While targeted therapy and immunotherapy has emerged as effective way to treat various malignant tumors, including lung cancer, reports on PLELC are relatively scarce.<\/jats:p>\n          <jats:p>CASE SUMMARY<\/jats:p>\n          <jats:p>A 38-year-old man was diagnosed with right PLELC. Chest computed tomography (CT) revealed a mass in the medial segment of the middle lobe of the right lung, with lymph node metastasis in the mediastinum and right hilum of the lung. CT-guided lung tumor biopsy was performed and the postoperative pathological examination combined with immune phenotype analysis and in situ hybridization confirmed PLELC. Standard molecular testing for patients with non-small cell lung cancer was negative and programmed cell death ligand-1 expression was about 2%. The patient declined radiotherapy and chemotherapy. Consequently, immunotherapy was administered, which included toripalimab 240 mg on day 1 and anlotinib 10 mg on days 1-14 for 10 cycles, followed by a maintenance dose of anlotinib 10 mg daily every 3 weeks. As a result, his progression-free survival reached 48 months.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>A combination of toripalimab and anlotinib may benefit patients with advanced diseases who have not received systematic antitumor therapy.<\/jats:p>","DOI":"10.5306\/wjco.v16.i4.104413","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:01:31Z","timestamp":1742950891000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis and treatment of pulmonary lymphoepithelioma-like carcinoma: A case report"],"prefix":"10.5306","volume":"16","author":[{"given":"Feng-Ling","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Mei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan-Da","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2021.757085"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930360413"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.007"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S241337"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2021.10.010"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivw064"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01487"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153043"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626566"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5028"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v16.i5.1436"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206294031240404071838"}],"container-title":["World Journal of Clinical Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i4\/104413.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i4\/104413.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:03:26Z","timestamp":1742951006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i4\/104413.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":12,"journal-issue":{"issue":"4"},"alternative-id":["104413"],"URL":"https:\/\/doi.org\/10.5306\/wjco.v16.i4.104413","relation":{},"ISSN":["2218-4333"],"issn-type":[{"value":"2218-4333","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}